| Dr Benita Marie Jackson, MD | |
|
7252 Tumblebrook Dr, New Albany, OH 43054-8891 | |
| (614) 933-0095 | |
| Not Available |
| Full Name | Dr Benita Marie Jackson |
|---|---|
| Gender | Female |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 7252 Tumblebrook Dr, New Albany, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1699832709 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | 35-061647 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Benita Marie Jackson, MD 7252 Tumblebrook Dr, New Albany, OH 43054-8891 Ph: (614) 933-0095 | Dr Benita Marie Jackson, MD 7252 Tumblebrook Dr, New Albany, OH 43054-8891 Ph: (614) 933-0095 |
News Archive
In May 2000, Raul Silva was involved in a motorcycle accident in Baja California, Mexico, badly breaking his left femur, or thighbone. He underwent emergency surgery in Mexicali and, at first, everything seemed fine. Then an infection set in, worsened, and Silva eventually made his way to San Diego, where his left leg was amputated.
Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.
The issue of Medicare payment cuts to doctors still looms, causing some physicians to shun Medicare patients and others to push for greater reform. Many worry that doctors may boycott the program if the planned 21 percent cut in payment rates goes through in 2010 while others complain about low Medicare reimbursement rates for certain procedures and geographic areas.
The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove the spleen.
› Verified 4 days ago